See other companies on Welcome to the Jungle

Spiden

Real-time biomarker and drug monitoring

Spiden logo
21-100 employees
  • Healthcare
  • B2B
  • Analytics
  • Biology
  • Machine Learning
  • MedTech
Pfäffikon, Freienbach, SZ

Jump to section

Company mission

To reach the holy grail of continuous, non-invasive, and medical grade multi-biomarker monitoring, in a next generation wearable, providing us with data to live longer, healthier lives.

Our take

For many in the healthcare space, it has been determined that personalized medical care is the next step in improving patient outcomes around the globe. Spiden is looking to be a part of this next generation of healthcare, providing wearables that continuously monitor biomarkers and drugs in the blood.

Smartly, the company has chosen to target glucose first. This gives them an entry to the glucose monitoring device market that represents a growing proportion of the $50 billion diabetes care sector. Beyond this, Spiden's combination of advanced spectral techniques and data analysis, alongside its "novel approach for technology miniaturization", sets it up to expand into any number of healthcare branches and niches.

Early in 2024, Spiden announced a breakthrough in its research, with its team achieving test results that showed only a 9% Mean Absolute Relative Difference (MARD) from the gold-standard measurement. It has also secured $15 million in additional funding which will support the conclusion of its first R&D phase.

Steph headshot

Steph

Company Specialist at Welcome to the Jungle

Benefits

  • Front-row seat to cutting-edge health technology
  • Mentorship & career growth opportunities
  • Flexibility in working hours - we encourage you to find your own balance between your work and personal life
  • Equity
  • Comprehensive healthcare, including vision and dental benefits

Company values

  • We care to do good, having awareness and empathy for the uniqueness of each individual life
  • We aim to create a better world jointly with and for our partners
  • We cultivate a strong and mindful self and team, appreciating our diversity in all its aspects
  • We make the most out of our talents, time and financial resources
  • We dream big and think long term, whilst focusing on the next simple step
  • We create trust through transparency, always remaining fact based and proactively open about our results

Funding (last 2 of 3 rounds)

Jan 2024

$15m

CONVERTIBLE

Apr 2021

$18m

EARLY VC

Total funding: $40.3m

Leadership

Leo Grünstein

(CEO)

Co-founder and Board Member at Caeli Nova, and Chairman at LG Capital. Former Co-founder and Board Member at MoneyPark, and also worked at McKinsey & Company as an Engagement Manager.

Diversity, Equity & Inclusion at Spiden

  • Diversity & equal opportunity: With 18 nationalities in the company, we strive to build a highly diverse and exciting environment. We take special care of gender diversity - currently balanced at 50/50 among the permanent employees.